CLINICAL TRIALS PROFILE FOR AFINITOR DISPERZ
✉ Email this page to a colleague
All Clinical Trials for afinitor disperz
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04195750 ↗ | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | Recruiting | Merck Sharp & Dohme Corp. | Phase 3 | 2020-02-27 | The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for afinitor disperz
Condition Name
Clinical Trial Locations for afinitor disperz
Trials by Country
Clinical Trial Progress for afinitor disperz
Clinical Trial Phase
Clinical Trial Sponsors for afinitor disperz
Sponsor Name